Patent · US Active

Single-dose administration of Factor VIIa

US9029324B2 · kind B2 · utility

1Cited by

9References

9Claims

0Family size

Assignee

Novo Nordisk Health Care AG · CH

Inventor

Ulla Hedner · Malmö, SE

Key dates

Filing date	May 28, 2008
Grant date	May 12, 2015
Priority date	—
Expiry date	Jan 21, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21021
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.